IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+4.48%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$329M
AUM Growth
+$329M
(-8.3%)
Cap. Flow
-$30.4M
Cap. Flow
% of AUM
-9.26%
Top 10 Holdings %
Top 10 Hldgs %
51.54%
Holding
77
New
13
Increased
17
Reduced
12
Closed
16
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$11.4M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$8.92M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$6.89M |
| 4 |
Gilead Sciences
GILD
|
$6.7M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$6.65M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$40.5M |
| 2 |
Alkermes
ALKS
|
$16.7M |
| 3 |
Exelixis
EXEL
|
$10.5M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$8.48M |
| 5 |
Sanofi
SNY
|
$7.81M |
Sector Composition
| 1 | Healthcare | 99.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amgen
AMGN
$155B
| $26M | 7.92% | 117,246 +26,000 | +28% | +$5.77M |
|
2
Incyte
INCY
$16.5B
| $22.3M | 6.79% | 358,454 +79,454 | +28% | +$4.94M |
|
3
Harmony Biosciences
HRMY
$2.12B
| $20.1M | 6.11% | 570,500 | – | – |
|
|
4
Regeneron Pharmaceuticals
REGN
$61.5B
| $19.4M | 5.91% | 27,000 +15,800 | +141% | +$11.4M |
|
5
Supernus Pharmaceuticals
SUPN
$2.53B
| $15.7M | 4.79% | 523,500 +100,000 | +24% | +$3.01M |
|
6
Vera Therapeutics
VERA
$1.38B
| $15.6M | 4.76% | 975,227 -27,030 | -3% | -$434K |
|
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $15.5M | 4.72% | 81,600 +35,000 | +75% | +$6.65M |
|
|
8
Apellis Pharmaceuticals
APLS
$3.48B
| $11.8M | 3.6% | 129,700 +98,000 | +309% | +$8.92M |
|
9
United Therapeutics
UTHR
$13.8B
| $11.6M | 3.55% | 52,759 +24,259 | +85% | +$5.36M |
|
|
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.2M | 3.4% | 176,856 -81,000 | -31% | -$5.12M |
|
|
11
Gilead Sciences
GILD
$140B
| $11.1M | 3.39% | 144,584 +87,000 | +151% | +$6.7M |
|
12
Illumina
ILMN
$15.8B
| $9.46M | 2.88% | 50,500 +24,000 | +91% | +$4.5M |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.39M | 2.86% | 260,000 +16,000 | +7% | +$578K |
|
14
Vertex Pharmaceuticals
VRTX
$100B
| $7.39M | 2.25% | 21,000 -12,000 | -36% | -$4.22M |
|
|
RVNC
15
DELISTED
Revance Therapeutics, Inc.
RVNC
| $7.3M | 2.22% | 288,726 +105,726 | +58% | +$2.67M |
|
|
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.89M | 2.1% | +67,000 | New | +$6.89M |
|
17
Travere Therapeutics
TVTX
$1.56B
| $6.77M | 2.06% | 441,019 +300,000 | +213% | +$4.61M |
|
18
Neurocrine Biosciences
NBIX
$13.8B
| $6.49M | 1.98% | +68,877 | New | +$6.49M |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.57M | 1.69% | 25,700 +14,700 | +134% | +$3.18M |
|
20
Aurinia Pharmaceuticals
AUPH
$1.58B
| $5.55M | 1.69% | 573,530 | – | – |
|
21
Denali Therapeutics
DNLI
$2.23B
| $5.54M | 1.69% | 188,000 +101,425 | +117% | +$2.99M |
|
22
Krystal Biotech
KRYS
$4.27B
| $5.39M | 1.64% | 45,945 -15,055 | -25% | -$1.77M |
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $5.08M | 1.55% | 58,656 | – | – |
|
24
Madrigal Pharmaceuticals
MDGL
$9.76B
| $4.23M | 1.29% | +18,300 | New | +$4.23M |
|
25
Axsome Therapeutics
AXSM
$6.05B
| $4.19M | 1.27% | +58,300 | New | +$4.19M |
|